口服阿苯达唑脂质体治疗沙鼠骨细粒棘球蚴病的实验研究

目的通过动物实验来验证口服阿苯达唑脂质体对骨包虫病的疗效。方法将20只已确认感染骨细粒棘球蚴的子午沙鼠随机分成4组,每组5只,A组为对照组,B、C、D 3组为给药组,给药组采用阿苯达唑脂质体混悬液经口灌胃100 mg/kg.d,连续治疗3个月,分别于30、609、0 d处死给药组动物,测定血液和包虫囊液中的药物及其代谢产物的浓度,于90 d处死对照组动物;对骨包虫病变进行大体及镜下观察;取完整肝脏和肾脏,制备光镜病理切片进行观察。结果经口灌胃连续治疗30 d后,血液中的平均药物浓度及囊内药物浓度基本稳定,统计分析血液中的平均药物浓度和囊内药物浓度差异,有统计学意义(P<0.05),30、60、90 d之间无统计学差异(P>0.05),囊内平均药物浓度(平均为0.494 mg/L)为血药浓度(平均为5.023 mg/L)的1/10。骨包虫囊继续生长,囊肿表面光滑,色清亮,张力高,形态正常,病理切片观察包虫囊生发层和角质层无改变。但角质层偶有钙化。实验动物的肝脏和肾脏无病理形态改变。实验期内未观察到阿苯哒唑脂质体药物本身有明显不良作用。结论口服阿苯达唑脂质体对骨包虫病没有明确治疗效果。

Experimental study on efficacy of liposomal albendazole administrated orally against bone echinococciasis granulosus

Objective To investigate the efficacy of albendazole liposome in bone hydatidosis. Methods Medication administration groups were sacrificed separately at 30,60,and 90 d,and tested the concentration of albendazole and its metabolite in blood and hydatid fluid;control group was sacrificed at 90 d,the hydatid lesions were observed in general and under microscope.Animal's liver and kidney were taken for pathological examination.Results The drug concentrations in blood and hydatid fluid were stable 30 days later,there were statistical significance between drug concentration in blood and in hydatid fluid,but there were no statistical significance between different times.The drug concentration in hydatid fluid(proximally 0.5 mg/L) was 1/10 of blood drug concentration(proximally 5 mg/L).Cysts grew continually after treatment,hydatid cysts were clear,slick and eumorphism,has high tension.The corneous layer and germinal layer of cysts have no damage,but the corneous layers calcified occasionally.Pathologic changes were not fond by pathologic examination in animals' kidney and liver.No significant side effects were observed during experiment period.Conclusion Oral administrated albendazole liposome suspension has no significant therapeutic efficacy to bone hydatid disease.